In a recent interview at SNMMI conference, Merle Hoenig, Ph.D., discussed new tau PET research examining genetic and modifiable risk factors that contribute to the progression of Alzheimer’s disease.
We scan the top radiology sources so you don’t have to.
From AI breakthroughs to imaging trends, we serve up real-time radiology insights.
-
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
-
‘I’m Telling You for the Last Time’ (Said No Radiologist Who Was Ever Taken Seriously)
Whether it comes in the form of seemingly extraneous addendums or the need to emphasize key points in radiology reporting, repetition can be a constant source of frustration.
-
SNMMI: Preliminary Research Suggests Dual-Targeting Radiopharmaceutical May Have Impact in Multiple Cancers
The dual-targeted 177Lu-DOTA-FAPI-RGD reportedly reduced or stopped the growth of cancer lesions in 88.9 percent of advanced adenocarcinomas in a small cohort of patients with varied cancers including pulmonary, pancreatic and ovarian cancer, according to new research presented at the SNMMI conference.
-
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
-
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
-
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
-
Diagnostic Imaging's Weekly Scan: June 15 — June 21
Catch up on the top radiology content of the past week.
-
FDA Clears AI-Powered Fetal Ultrasound Analysis Software from DeepEcho
The AI software reportedly facilitates ease of use and improved accuracy in fetal ultrasound evaluations.
-
Mammography Screening Linked to Greater than 14 Percent Higher Five- and 10-Year Survival Rates for Breast Cancer
In a study involving over 1,000 women with breast cancer, researchers found that patients with screening-detected breast cancer had a five-year survival rate of 94.4 percent in comparison to 79.6 percent for women with clinically detected breast cancer.